IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) major shareholder Shih-Yao David Lin purchased 18,161 shares of the business’s stock in a transaction on Friday, June 6th. The shares were bought at an average price of $0.97 per share, for a total transaction of $17,616.17. Following the purchase, the insider directly owned 588,345 shares in the company, valued at $570,694.65. This represents a 3.19% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
IRIDEX Trading Up 29.4%
NASDAQ IRIX opened at $0.88 on Thursday. IRIDEX Corporation has a 12-month low of $0.61 and a 12-month high of $1.65. The company has a fifty day simple moving average of $0.73 and a two-hundred day simple moving average of $0.95. The stock has a market cap of $15.46 million, a P/E ratio of -4.40 and a beta of 0.67.
IRIDEX (NASDAQ:IRIX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The firm had revenue of $12.57 million for the quarter, compared to analysts’ expectations of $13.59 million. As a group, sell-side analysts forecast that IRIDEX Corporation will post -0.12 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on IRIDEX
Institutional Trading of IRIDEX
Several institutional investors and hedge funds have recently bought and sold shares of IRIX. United Capital Financial Advisors LLC acquired a new stake in IRIDEX during the 2nd quarter valued at approximately $41,000. Weber Capital Management LLC ADV acquired a new stake in shares of IRIDEX in the second quarter worth $206,616. Diversify Advisory Services LLC purchased a new position in shares of IRIDEX during the second quarter worth $30,000. Bank of New York Mellon Corp purchased a new position in shares of IRIDEX during the second quarter worth $29,000. Finally, Renaissance Technologies LLC lifted its position in IRIDEX by 6.7% during the first quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock valued at $401,000 after purchasing an additional 25,067 shares during the period. 20.10% of the stock is currently owned by institutional investors and hedge funds.
Key Headlines Impacting IRIDEX
Here are the key news stories impacting IRIDEX this week:
- Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
- Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
- Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
- Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.
IRIDEX Company Profile
IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.
The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.
Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.
Featured Articles
- Five stocks we like better than IRIDEX
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.
